NCT03870555View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

May 16, 2019

Study Completion Date

May 16, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-954

TAK-954 infusion administered intravenously.

DRUG

TAK-954 Placebo

TAK-954 placebo-matching infusion intravenous.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY